Key takeaways
Skyrizi (risankizumab) and Simponi (golimumab) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Skyrizi is an interleukin antagonist that targets IL-23 to reduce inflammation, while Simponi is a monoclonal antibody that blocks TNF to achieve a similiar effect. Skyrizi is used for plaque psoriasis, psoriatic arthritis, and Crohn's disease, whereas Simponi treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Skyrizi is typically administered every 2 to 3 months after initial doses, while Simponi is usually given once a month after starter doses. Both medications can be self-injected under the skin at home after training. Simponi also comes in an intravenous form called Simponi Aria, which can only be administered by a healthcare professional. Both medications can increase the risk of infections, but Simponi also has warnings for potential cancer risks and heart failure. Skyrizi is available as a prefilled syringe, pen, and on-body injector. Simponi only comes in prefilled syringe and autoinjector forms.
